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ABSTRACT 
 
Effects of Bioactive Compounds from Different Potato Genotypes on Prostate Cancer 
Development in Athymic Nude Mice. (May 2012) 
Sarah Diane Turner, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. J. Creighton Miller, Jr. 
 
 
Phytochemicals are widely noted for their role in chemoprevention. Potato (Solanum 
tuberosum L.) is the third most important food crop worldwide and is considered a 
significant source of antioxidants, providing an ideal delivery system for beneficial 
compounds. The anti-proliferative and pro-apoptotic properties of potato bioactive 
compounds have been reported in vitro on human prostate cancer cell lines. However, in 
vivo studies are limited, and more information is needed to determine the 
chemopreventive properties of potato in the diet.  
 
The objective of this study was to evaluate the effects of potato bioactives on prostate 
cancer in vivo using a mouse model. Athymic nude mice received xenografts of human 
prostate cancer cells (PC-3) and were administered extracts of potato bioactives from 
either the white flesh Solanum bulbocastanum (PI243510) or CO112F2-2P/P (purple-
flesh Colorado selection), while control mice received water. Neither potato extract 
provided a significant reduction in tumor growth nor reduced levels of the pro-
angiogenic protein VEGF, but the S. bulbocastanum extract reduced expression of 
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metastasis associated protein 1 (MTA1) in tumors, and both potato extracts reduced 
MTA1 expression in lungs, suggesting the need for further research on the potential 
chemopreventive or chemotherapeutic properties of potato bioactives.   
 v 
DEDICATION 
 
This thesis is dedicated to the mice used in this study and to the 
potato, my favorite vegetable. 
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1.  INTRODUCTION  
 
Potato (Solanum tuberosum L.) is the third most important food crop worldwide and the 
leading vegetable crop in the United States, with a per capita consumption of ~117lbs in 
2010 (1). Potatoes represent up to 32% of the vegetable consumption in the US (2), 
providing an ideal system for the delivery of health promoting phytochemicals via the 
diet. Phytochemicals are widely noted for their role in the prevention of chronic illnesses 
and are well documented as chemopreventive agents (2-10). Thus, increasing the amount 
of phytochemicals in potato, such as phenolics, carotenoids, and glycoalkaloids, may 
offer a practical means of delivering health promoting compounds and changing the 
market perception of both fresh and processed potato products (9,11-15). 
 
Prior investigations have indicated that potato extracts exhibit cytotoxic activity against 
prostate cancer cell cultures (2,9,10). In Western countries, prostate adenocarcinoma is 
the second leading cause of cancer-related death in males (8,16,17), with one in 36 males 
dying of related complications (17). For 2010, it is estimated that there were 217,730 
new cases of prostate cancer and 32,050 prostate-cancer-related deaths (16). Dietary 
prevention is a viable mechanism for reducing the incidence of prostate cancer, based on 
the late onset and delayed progression of the disease (10). Onset is around 50 years of 
age, with progression occurring in approximately 10 to 20 years (16).  
 
____________ 
This thesis follows the style of Nutrition and Cancer.  
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This study was designed to further evaluate the anti-prostate cancer activity of potato, 
which would improve the marketability of potato as part of a healthy diet. The objective 
was to evaluate the anti-prostate-cancer activity of potato bioactives in a tumor xenograft 
model. This experiment also compared two genotypes of potato, a purple-flesh, 
Colorado breeding line (CO112F2-2P/P), which was selected for high phenolic content 
and antioxidant activity (18), and a white-flesh accession of Solanum bulbocastanum 
(PI243510), a wild relative of the cultivated potato with a diverse glycoalkaloid profile 
(19). This study examined the effects of potato bioactives on tumor growth, factors 
related to cancer progression, and body weight as a measurement of overall health. 
Information gathered can be utilized to promote selection of potato cultivars with a 
higher content of beneficial compounds.  
 
 
1.1 Bioactive Compounds in Potato  
Phytochemicals, many of which function as antioxidants and have anticarcinogenic 
activity (2,3,5-10,13,20), represent a diverse group of secondary metabolites that are 
produced in response to biotic and abiotic stresses (21). The major classes of 
phytochemicals are carotenoids, phenolics, alkaloids, nitrogen-containing compounds, 
and organosulfur compounds (4). Potato germplasm primarily contains phenolics, 
carotenoids, and alkaloids, in addition to other antioxidants such as glutathione, which 
maintains the quality and levels of other antioxidants, vitamin C, selenium, α-lipoic acid, 
and α-tocopherol (5,14,21,22). Andre et al. (15) reported that potatoes rank third in the 
daily intake of phenolics and antioxidants from fruits and vegetables, providing an 
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average daily polyphenol intake of 64 mg per capita in the US (14). Potatoes are also a 
good source of other nutrients, such as proteins, carbohydrates, potassium, phosphorus, 
magnesium and vitamins B6 and B3 (15). 
 
Phenolics 
Phenolic compounds are the most abundant phytochemicals in potato (15) and include 
phenolic acids, flavonoids, stibenes, coumarins, and tannins (4,6,23,24). In potatoes, the 
major phenolics are phenolic acids and flavonoids. Phenolics also exist in free and 
bound states, of which the latter remains bioavailable in the colon, providing more 
opportunities for health promoting activity (6). Most fresh vegetables are only capable of 
releasing about one fourth of their phenolics in the colon, while up to half of potato 
bioactives can potentially be absorbed (6). 
 
The phenolic content of potatoes is highly characterized. Phenolic acids, mostly 
chlorogenic acid, constitute 45-90% of the total phenolic content in potatoes (15,21). Up 
to 50% of the phenolic content is found in the skin and surrounding tissues, decreasing 
towards the center of the tuber (21). Tuber skin primarily contains chlorogenic, 
protocatechuic, and caffeic acids (18), but vannilic, p-coumaric, ferulic, sinapic, 
salicylic, and many unidentified phenolic acids are also present (23).  In tuber flesh, the 
major phenolic acid is chlorogenic acid, but low concentrations of caffeic, 
protocatechuic, p-coumaric, ferulic, gallic, and sinapic acids are also present (23).  
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Flavonoids are categorized as flavonols, flavones, flavanones, anthocyanidins, and 
isoflavonoids. The flavonols kaempferol, quercetin, and myricetin are found in tuber 
flesh, but are not major contributors to the phenolic activity of potatoes (23). Trace 
amounts of catechin, epicatechin, and eriodictyol are also found in tuber flesh (23). 
Moderate amounts of flavanones, in particular eriodictyol and naringenin, are also found 
in tuber skin (23). Phenolic acids do not impact the color of tuber skin and flesh, while 
anthocyanins are responsible for red-, blue-, and purple-flesh colors (23,25). 
Comparatively, red- or purple-flesh potatoes have approximately two to threefold the 
antioxidant content found in white-flesh potatoes (26-28), levels which are competitive 
with brussels sprouts and spinach (26). The primary glycosides in red potatoes are 
pelargonidin and peonidin, while purple potatoes contain glycosides of pelargonidin, 
malvidin, delphinidin, peonidin, and petunidin (14,28).  
 
Chu et al. (6) estimated the quality and quantity of phenolics found in the ten most 
common vegetables in the US (broccoli, spinach, yellow onion, red pepper, carrot, 
cabbage, potato, lettuce, celery, and cucumber). Of the ten vegetables analyzed, potato 
had the highest content of bound phenolics (39.9%), a total phenolic content of 23.31 ± 
5.83 mg gallic acid equivalents (GAE) /100 g FW, and a total antioxidant activity of 
4.86 ± 0.2 µmol of vitamin C equiv/g FW of sample. Potato ranked eighth out of 10 for 
antioxidant activity and seventh out of 10 for total phenolic content, but Nzaramba et al. 
(7) suggested that potato ranks second when per capita consumption is considered. It is 
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also worth noting that the study by Chu et al. (6) study did not account for genetic 
variation, which plays a major role in phenolic content.  
 
Carotenoids 
Andre et al. (15) reported that degree of yellow pigmentation was strongly correlated 
with carotenoid content. In potatoes, the major carotenoids in tuber flesh are 
xanthophylls, namely lutein, neoxanthin, zeaxanthin, antheraxanthin, and violaxanthin, 
which are all putative antioxidants (15,23,25,26). The potentially major contributors to 
total carotenoid content in yellow-fleshed tubers are zeaxanthin (6-43%) and lutein (9-
27%).  
 
Glycoalkaloids 
In addition to phenolic compounds, potatoes also contain glycoalkaloids, a class of 
secondary metabolites that cause adverse symptoms at high levels, but also exhibit 
beneficial effects, including anticancer activity (19,29,30). Glycoalkaloids are valued for 
their role as plant defense compounds, providing protection against various pathogens 
and herbivores, but considered are antinutrients in the human diet (8,29,30). As a result, 
glycoalkaloid content is strictly monitored in commercial potatoes.  
 
Glycoalkaloids are derived from cholesterol and are characterized by an oligosaccharide, 
a C27 steroid, and a heterocyclic nitrogen component (19). There are two major classes 
of glycoalkaloids, solanidane aglycones and spirosolane aglycones (19). The 
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glycoalkaloids solanine and chaconine account for over 90% of the total glycoalkaloid 
(TGA) content in cultivated potatoes, with chaconine occurring in higher concentrations 
(19). However, the diversity and biosynthesis of glycoalkaloids in potato is not well 
characterized (19). Wild species of Solanum contain many novel glycoalkaloids not 
found in cultivated potatoes, providing a resource for genetic variability (8,19).  
 
TGA in potatoes is estimated as the combined amounts of α-solanine and α-chaconine 
(mg TGA/kg) and cannot exceed 200 mg/kg of potato, at which point potatoes develop a 
bitter taste and consumption causes adverse symptoms (19,30-32). Mild exposure to 
glycoalkaloids results in gastrointestinal discomfort (nausea, vomiting, diarrhea), and 
may aggravate irritable bowel syndrome, while severe exposure may result in 
neurological responses (19,32,33). There is also evidence that glycoalkaloids have 
cardio-toxic and teratogenic effects (34,35). The toxicity of glycoalkaloids primarily 
results from disruption of cell membranes and inhibition of acetocholinesterase (AChE) 
(30,33,35,36). It is possible that different types of glycoalkaloids, such as those found in 
wild species, have different toxic effects on mammals (32). Beneficial effects of 
glycoalkaloids include the potential to lower cholesterol, antipyretic and anti-
inflammatory activity (29), antibiosis against foodborne pathogens (37), and anticancer 
activity (19,38).  
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Genotypic Variation 
Genetic variability for the expression of beneficial compounds can be exploited to 
produce cultivars with improved health value (3,26). Because antioxidant levels are 
generally only studied in cultivated potato, Andre et al. (15) and Nzaramba et al. (7,8) 
suggested the use of wild potato germplasm to incorporate genetic variability for 
phytochemical content.  Potato phenotypes include varying combinations of skin and 
flesh colors, namely white, yellow, red, and purple.  
 
The white or yellow flesh phenotype is thought to be determined by a single gene (26). 
Red and blue pigmentation result from anthocyanin content and are controlled by a 
sequence of single genes, which behave in a syntenic fashion and are considered part of 
a single genome (26). However, degree of pigmentation does not adhere to simple 
genetic control and may be influenced by epistatic interactions (7,11,26).  
 
Antioxidant profiles vary largely among genotypes and antioxidant pathways appear to 
be under independent control (3,15). Tetraploid cultivars of potato express only acylated 
forms of anthocyanidin glycosides, but both acylated and non-acylated forms are found 
in diploid genotypes (11). High levels of carotenoids can also be found in diploid 
germplasm and may offer an additional source of variation (39). Thus, there is potential 
to augment the bioactive content of tetraploid potato cultivars by introgression from 
diploid genotypes (8,19).   
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Total glycoalkaloid content is also dependent on genotype (30,31,40) and is considered a 
highly heritable, quantitative trait (32). Although cultivated potato contains primarily α-
chaconine and α-solanine, wild species contain many uncharacterized glycoalkaloids, 
which have different chemical properties. Shakya and Navarre (19) suggested that these 
traits could be introgressed into cultivated potato varieties to improve nutritional content, 
possibly by replacing solanine and chaconine with less toxic glycoalkaloids, such as 
tomatine.  
 
Effects of Growing Environment, Postharvest Storage, and Cooking Method  
Andre et al. (15) proposed that environmental factors may impact pathways related to 
phenolic composition. There is evidence that high altitude environments with long days 
and cool temperatures promote increases in anthocyanin and phenolic content (28). 
Nzaramba et al. (7) compared greenhouse and field tuber production and found that 
various Solanum species had greater antioxidant activity and phenolic content when 
grown under field conditions. Tubers harvested at greater maturity expressed higher 
levels of anthocyanins and phenolics and minimal levels of glycoalkaloids (41).  In 
addition, Reyes et al. suggested that abiotic stresses could be applied to augment the 
synthesis of phenolic compounds, thereby increasing the health value of fresh produce 
(13,20).  
 
Potatoes are commonly stored and cooked prior to consumption, both of which impact 
phytochemical levels (42). Cold storage at 4ºC over several months induced a significant 
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increase in anthocyanin content (12,28,42) as well as increased antioxidant activity, total 
phenolics, and carotenoid content relative to non-stored tubers (42), with ratios of 
individual compounds remaining constant (28). However, increases in anthocyanin 
content were not observed when tubers were stored at higher temperatures (28). The 
increase in phenolic content is not attributed to water loss, but to the synthesis of 
anthocyanins, which may be connected to increased sugar production during storage 
(28). 
 
Various cooking methods, such as baking, boiling, microwaving, and frying, also 
influence phytochemical levels, with red- and purple-flesh potatoes maintaining equal to 
or greater than 75% of their anthocyanin content (26). Some studies suggest that cooking 
preserves or increases phytonutrient content (28,42). In a study by Blessington et al. 
(42), baked, boiled, fried, and microwaved potato samples were compared to raw tubers. 
All treatments had increased amounts of chlorogenic and vanillic acids. Baked, fried, 
and microwaved samples had greater levels of caffeic and p-coumaric acids, and 
microwaved samples had an increased content of epicatechin. Of the cooking methods 
used in this study, boiling resulted in the lowest phenolic content. Lachman et al. (28) 
reported similar results and suggested that retention of anthocyanins is more efficient in 
baked, microwaved, or steamed potatoes relative to boiled or uncooked tubers. However, 
Brown et al. (27) reported that boiling increased antioxidant activity. The increase in 
phenolic content during the cooking process was attributed to increased extractability of 
compounds and the conversion of complex polyphenols into more soluble forms (28,42). 
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In contrast, Perla et al. (22) concluded that boiling, microwaving, and baking 
significantly reduced phenolics and that losses were minimized by boiling. Variability in 
conclusions is likely due to different cooking conditions, such as duration and 
temperature. In relation to glycoalkaloid content, various cooking methods had little to 
no effect (31,32,34), unless potatoes were peeled, in which case glycoalkaloid content 
was reduced (30). 
 
Acrylamide is a toxic, potentially carcinogenic compound produced in fried potato 
products (43). Acrylamide is produced by the Maillard reaction, in which the carbonyl 
group of reducing sugars reacts with the nucleophilic amino group found in amino acids, 
peptides, and proteins. Zhu et al. (43) analyzed 16 potato varieties to determine the 
relationship between acrylamide content, concentration of reducing sugars, and phenolic 
content. The tuber concentrations of fructose, glucose, and asparagine were positively 
correlated with acrylamide production. In addition, high content of phenolic compounds 
was connected to lower levels of acrylamide (43). Antioxidants are also known to reduce 
acrylamide levels by interacting with the Maillard reaction. Based on these results, Zhu 
et al. (43) suggested that acrylamide levels may be reduced by breeding for lower 
concentrations of reducing sugars and asparagine and higher concentrations of phenolics 
and other antioxidants. 
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1.2 Prostate Cancer 
Prostate adenocarcinoma (PCa) is the second leading cause of cancer-related death in 
males in Western countries, largely in relation to diet (8,16,17). For 2010, it is estimated 
that there were 217,730 new cases of prostate cancer and 32,050 prostate-cancer-related 
deaths (16). One in 36 males die of related complications (17) and the major cause of 
mortality is skeletal metastasis (44,45).  Prostate cancer develops later in life at around 
50 years of age, with progression occurring in approximately 10-20 years (16).  
 
Carcinogenesis is often characterized in terms of three major stages: initiation, 
promotion, and progression (46,47). Thus, potential treatments for PCa often target the 
prevention of initiation, the inhibition of promotion, and the treatment of premalignant 
stages (46). Initiation is a rapid and irreversible process involving mutagenesis and DNA 
damage by reactive species (46), with no observable effects on morphology at the 
cellular or tissue level (47). Promotion is a prolonged, reversible process (46,47) that 
reduces the sensitivity of tissues to growth restraints via wounding or inflammation of 
normal tissue (47), which results in the development of a nonmalignant tumor (46,47). 
Promotion relies on increased blood flow (47), and therefore inhibition of blood vessel 
formation, or angiogenesis, is a common target for intervention (48). Progression occurs 
when a tumor develops invasive or metastatic potential (46,47). At this stage, cells are 
able to enter the blood stream and colonize additional tissues (44).  
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The initiation, promotion, and progression of PCa is a complex process involving more 
than one genetic event and various molecular processes, many of which are not well 
understood (44,45). Initiation of PCa involves the production of mutated cells in the 
epithelial layers of the prostate (45). Promotion is characterized by hyperproliferation of 
cells, resulting in prostatic intraepithelial neoplasia (PIN), which is the precursor for the 
development of a benign tumor, which is classified as high-grade PIN (HGPIN) (45). 
Early stages of PCa are androgen dependent (44,45), thus androgen deprivation therapy, 
or chemical castration, is a viable method of treatment and results in tumor regression 
(45). Many cases relapse and, as PCa develops, cells experience additional mutations 
and can become hormone refractory (44,45). These cells are insensitive or resistant to 
chemical castration and non-hormonal treatments for androgen resistant PCa have 
limited efficacy (44). Progression of PCa often involves lymphatic metastasis to regional 
nodes and the skeletal system (44). 
 
There are many molecular pathways involved in the various stages of PCa development 
(45), and thus many opportunities for intervention, which can be accomplished by 
prevention of mutagenesis, antiproliferative activity, induction of apoptosis 
(programmed cell death), and inhibition of angiogenesis and metastasis (10,44). These 
processes can be regulated by activating or deactivating cell cycle proteins, 
inflammatory proteins, enzymes, and cytokines, as well as transcription factors and 
growth factors (9,10,44,49). Angiogenesis is commonly targeted by reducing levels of 
vascular endothelial growth factor (VEGF), a protein which is associated with promotion 
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of cell proliferation, survival, and metastasis in many cancers (48). Metastasis associated 
protein 1 (MTA1) has also been linked to angiogenesis and metastasis, with evidence 
that high levels of MTA1 expression are correlated with poor prognosis in prostate 
cancer patients (50). Studies have shown that MTA1 inhibition can decrease malignancy 
in many cancer cells, such as melanoma and breast cancer cells (50). MTA1 has also 
been linked to the upregulation of VEGF (50). Kai et al. (50) demonstrated that MTA1 
deficient xenografts had reduced angiogenesis, smaller blood vessels, and reduced 
VEGF levels relative to MTA1-positive counterparts.   
 
Mouse models are commonly used to study the different stages of carcinogenesis and the 
efficacy of anticancer compounds (45). To study prostate cancer, the ideal mouse model 
would develop PIN, HGPIN, local invasive adenocarcinoma, and invasive cancer and/or 
androgen insensitivity, with eventual metastasis to the lymph nodes and skeleton (45). 
The xenograft mouse model involves the implantation of human cancer cells into 
immunodeficient mice, allowing a quick evaluation of a specific treatment, but does not 
characterize prostate cancer progression in humans (45).  There are also genetically 
engineered mouse models (GEMMs), which include transgenic models in which 
prostate-specific promoters are used to express various oncogenes, and traditional and 
non-traditional knockout models. GEMMs are not an ideal model as mutations may 
influence other physiological processes and are present throughout mouse development, 
whereas humans develop cancer via spontaneous mutation (45). Mice are also 3000 
times smaller and have a lifespan 30-50 times shorter than humans, thus there are 
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differences in the uptake and effects of potential cancer treatments (45). Valkenburg and 
Williams (45) suggested that a variety of models may be necessary to study the many 
aspects of prostate cancer. 
 
1.3 Anticancer Properties of Potato Bioactives 
Many epidemiological studies have elucidated the role of fruits and vegetables in 
reduced risk of chronic diseases, including many types of cancer (2,3,5-10,13,20). 
Results indicate that the most effective control of cancer development and progression is 
prevention rather than treatment (6,17). Phytochemicals offer a means of prevention by 
reducing oxidative stress (3,6,11), with five plus servings of fruits and vegetables 
reducing the risk of developing many cancer types by approximately half (2). Prevention 
is best accomplished by a combination of phytochemicals obtained from many sources 
(6), which coincides with the conclusion that it is more practical to consume plant 
products than individual compounds (7). 
 
Oxidative stress occurs in a cell via free radical damage, which can result from increased 
levels of reactive oxygen species (ROS) within the cell and/or a loss of cell antioxidant 
capacity (6). ROS are well documented as the causal agents of mutations, DNA 
breakage, DNA cross-linking, and chromosomal breakage and rearrangement, all of 
which can induce cancer development if left unrepaired (6). In the diet, the synergistic 
activity of antioxidants quenches free radicals, relieving oxidative stress (2,6). 
Phytochemicals aid in cancer prevention by averting DNA adduct formation, 
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neutralizing carcinogens, ameliorating inflammation, obstructing angiogenesis, and 
exerting cytotoxic effects on cancer cells (2,6,7,26). 
 
Phenolics, particularly anthocyanins, are linked to anticarcinogenic activity, such as 
apoptosis, inhibition of cell proliferation, and reduction of angiogenesis (3,9). Boivin et 
al. (2) assessed the anticancer properties of extracts from common fruits and vegetables 
on multiple human cancer cell lines. The use of whole extracts allowed an evaluation of 
the synergistic activity of many bioactives, as well as the ability to better represent 
human consumption. This study demonstrated that potato phytochemicals inhibit the 
proliferation of breast and prostate cancer cell lines up to 50%.  
 
Reddivari et al. (9,10) analyzed specialty potato extracts and their fractions for 
antiproliferative activity on androgen-dependent (LNCaP) and independent (PC-3) 
prostate cancer cell lines. The anthocyanin fraction induced caspase-dependent and 
independent apoptosis, with no evidence of necrosis. Of the lines evaluated, the 
CO112F2-2P/P cultivar ranked best in total phenolic content, antioxidant activity, and 
antiproliferative activity (9,10,18). Further investigation revealed that the potato 
bioactives α-chaconine and gallic acid were most effective at reducing LNCaP and PC-3 
cell proliferation (10).  
 
Although potentially toxic, glycoalkaloids promote apoptosis and reduce proliferation in 
human liver, cervical, lymphoma, stomach, and prostate cancer cell lines (8,19,38).  
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There is also a diverse array of glycoalkaloids, many of which are unidentified (19). 
Further characterization may allow the selection of potato cultivars with a higher content 
of health promoting glycoalkaloids (19). Nzaramba et al. (8) evaluated accessions of 
Solanum jamesii for antioxidant activity, phenolic content, glycoalkaloids, and 
antiproliferative activity on human colon and prostate cancer cells. The extracts inhibited 
cell proliferation in both cell lines without cytotoxicity, and antiproliferative activity 
varied based on genotype. There was no significant correlation between glycoalkaloid 
content and antiproliferative activity, but the pro-apoptotic activity of α-chaconine has 
been reported in human colon cancer cells (38). In addition, the antiproliferative activity 
of α-chaconine and α-tomatine on liver cancer cells was similar to the anticancer drug 
adriamycin (29). 
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2. MATERIALS AND METHODS 
 
2.1 Phytochemical Extraction and Phenolic Content  
Potato genotypes were selected based on prior screening for total phenolics, antioxidant 
activity, and unique metabolic profile (9,10,18). The potato breeding line CO112F2-2P/P 
(purple-flesh) was selected based on high phenolic content, antioxidant activity, and 
antiproliferative activity in prostate cancer cell cultures (9,10,18). This line was obtained 
from Dr. David Holm (Colorado State University, San Luis Valley Research Center).  
An accession of S. bulbocastanum (white-flesh, PI243510) was selected as it has a 
diverse glycoalkaloid profile (19), but relatively low amounts of solanine and chaconine, 
which are the glycoalkaloids known to cause toxicity in cultivated potatoes. This 
accession was provided by Dr. Roy Navarre (USDA-ARS, Prosser, Washington). Tuber 
material was diced into cubes and lyophilized.  
 
Phenolics were extracted using methanol acidified with formic acid (1 ml formic acid/L) 
(pH < 3.0) to maintain antioxidant stability (21). Lyophilized tuber tissue was 
homogenized with acidified methanol at a ratio of 1 g/5 ml. Samples were centrifuged in 
a JA-17 rotor (Beckman Coulter, Indianapolis, IN) at 31,000 g for 15 min, after which 
the supernatant was collected. The extraction was repeated on the pellet and the 
supernatant was collected. The extract was sterile filtered using a 0.22 µm 
polyethersulfone (PES) membrane. Following filtration, the extract was lyophilized to a 
powder and redissolved in cold, sterile water.  
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Total phenolic content of the extract was determined using the Folin-Ciocalteu 
colorimetric method (51). Extracts (150 µl) were diluted with 2400 µl of nanopure water 
and allowed to react with 150 µl of 0.25N Folin-Ciocalteu reagent for 3 min, at which 
point 300 µl of 1N Na2CO3 was added and allowed to react at room temperature in the 
dark for 2 h (18). Phenolic content was determined by absorbance at 725 nm and is 
reported as mg chlorogenic acid equivalents (CAE) per ml (18). The extracts were 
concentrated by rotovarporization to a final content of 3.75 mg CAE/ml. The control 
treatment was lyophilized extraction solvent resuspended in sterile water.  
 
2.2 Cell Culturing 
The androgen receptor (AR)-negative human prostate carcinoma cell line PC-3 was 
obtained from the American Type Culture Collection (Manassas, VA) and maintained at 
37°C in a 5% CO2 jacketed incubator in RPMI 1640 (Sigma-Aldrich, St. Louis, MO) 
supplemented with 2.38 g/L N-2-hydroxyethylpiperazine-N’-2-2ethanesulfonic acid 
(HEPES), 1.5 g/L sodium bicarbonate, 0.11 g/L sodium pyruvate, 4.5 g/L glucose, 100 
mL/L fetal bovine serum (FBS), 10 mL/L antibiotic antimycotic solution (Sigma-
Aldrich), and 0.2 g/L bovine serum albumin (BSA). Cells were passaged at 80% 
confluence.  
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2.3 In vivo PC-3 Tumor Xenograft Model 
Forty male athymic nude-Foxn1nu mice were obtained from Harlan Laboratories 
(Indianapolis, IN) and handled in accordance with the Animal Use Protocol #2010-39 
approved by the Texas A&M Institutional Animal Care and Use Committee (IACUC). 
The mice were housed and handled in sterile conditions at the Lab Animal Resources & 
Research (LARR) facility at Texas A&M University and monitored by Comparative 
Medicine Program (CMP) staff. Upon arrival, mice were given an acclimatization period 
of one week. 
 
PC-3 cells were combined with Matrigel (BD Biosciences, Franklin Lake, NJ) in a 1:1 
(v/v) ratio. Thirty mice received subcutaneous injections (½” 27 gauge needle) of 1.5 x 
106 PC-3 cells in each rear dorsal flank (50,52,53). Two weeks after cell injection, mice 
developed palpable tumors and were randomized by tumor volume and body weight. 
Mice were treated with extracts from either S. bulbocastanum (n = 10) or CO112F2-2P/P 
(n = 10) or a control (n = 9). Nine mice did not receive xenografts in order to observe the 
effects of potato bioactives on body weight in healthy mice. Mice without tumors 
received extracts from either S. bulbocastanum (n = 4) or CO112F2-2P/P (n = 5). 
Treatments (26 mg CAE/kg) were administered once every two days by oral gavage 
using a 20 G stainless steel curved needle. Tumor length, width, and height were 
measured once every four days using a Vernier caliper. An ellipsoid model, 
[π/6(l*w*h)], was used to estimate tumor volume (mm³) (53,54). Final tumor weight was 
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taken at the end of the study following surgical removal of the tumors. Body weight (g) 
was measured once every four days to track significant weight loss or gain. 
 
Mice were sacrificed if health significantly deteriorated or at the experimental endpoint, 
after which they were immediately placed on ice for tumor, liver, kidney, and lung 
collection. All tissues were placed into liquid nitrogen for protein analysis (50,53). The 
tumors were extracted and weighed. Liver and kidney tissues were analyzed for 
symptoms of toxicity, such as pallid color.  
 
2.4 Statistics 
One-way analysis of variance (ANOVA) was used to compare means. Significant 
differences were determined by Fisher’s LSD at 5% significance. Data are presented as 
means ± SE.  
  
2.5 Western Blot Analysis 
Tumor and lung tissues were analyzed via Western blot for protein expression related to 
angiogenesis and metastasis, namely vascular endothelial growth factor (VEGF) 
(Rockland Immunochemicals, Gilbertsville, PA) and metastasis-associated protein 1 
(MTA1) (Santa Cruz Biotechnology, Santa Cruz, CA) (50). Proteins were extracted into 
a high salt buffer [50 mM HEPES, 0.5 M NaCl, 1.5 mM MgCl₂, 1mM EGTA, 10% (v/v) 
glycerol, 1% (v/v) Triton-X-100]  containing 1% protease inhibitor cocktail (Sigma-
Aldrich) and 1% phosphatase inhibitor cocktail 2&3 (Sigma-Aldrich) and quantified 
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using Bradford reagent. Protein lysates were boiled with β-mercaptoethanol for 5 min at 
100°C. Proteins were separated using 7.5% (high molecular weight proteins) or 12% 
(low molecular weight proteins) sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) at 30 V for 12 h. Proteins were transferred by wet blotting 
onto a 0.2 μ polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA) by 
wet electroblotting in buffer containing 25 mM Tris, 192 mM glycine, and 20% 
methanol for 1.5 h at 0.90 Å. Membranes were blocked for 30 min with 3% milk TBST 
[10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 0.05% Tween, 3% non-fat dry milk] and 
incubated with primary antibody in either fresh 3% milk TBST or 3% BSA TBST 
overnight at 4°C with gentle shaking. Primary antibody concentrations were 1:200 for 
MTA1, 1:1000 for VEGF, and 1:5000 for β-actin, which was used as a loading control. 
Membranes were then washed with distilled water for 10 min (3x) and incubated with 
the secondary antibody, anti-IgG1 (1:5000) or anti-rabbit (1:5000), in 3% milk TBST 
overnight at 4°C. Membranes were washed with distilled water for 10 min (3x), 
incubated with chemiluminescence substrate for 1 min, and exposed using Kodak image 
station 4000 mm Pro (Carestreamhealth, Woodbridge, CT) (9,10,55).   
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3. RESULTS 
 
3.1 Tumor Growth Rate and Size 
 
Effects of potato bioactives on tumor growth were evaluated by measuring tumor 
volume over the course of the study. Mice were given xenografts of androgen receptor 
(AR)-negative PC-3 cells and were randomized into treatment groups by tumor volume 
(mm³) with means ± 1.22 SD of each other.  Treatments (0.75 mg CAE/dose) of extracts 
from either S. bulbocastanum or CO112F2-2P/P were administered every other day, with 
water serving as a control. Tumor volume was measured every four days, as illustrated 
in Figure 3.1A. The results show that the S. bulbocastanum and CO112F2-2P/P extracts 
did not significantly reduce tumor volume relative to the control. On day 22, the S. 
bulbocastanum treated mice had a significantly greater tumor volume than the control, 
but final tumor volume was not significantly different among treatments. To account for 
variability within treatment groups, growth rate was also evaluated by comparing final 
and initial tumor volume (Figure 3.1B). Growth rate was calculated using the formula 
[(final tumor volume-initial tumor volume)/initial tumor volume]. Tumor weights (g) 
were taken at the endpoint of the study as an additional measurement of tumor 
development (Figure 3.2). Again, there were no significant differences observed among 
treatments.   
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A 
 
B 
 
 
Figure 3.1. Tumor volume (mm³) was estimated using an ellipsoid model [π/6(l*w*h)] 
over the duration of the study (A) and as a comparison of final and initial tumor volume 
(B). All data are presented as means ± SE. No significant differences were detected 
among treatment groups (Fisher’s LSD at p<0.05), with the exception of day 22 (*) in 
Figure A, where the tumor volume of the S. bulbocastanum treated mice was 
significantly greater than that of the control (p=0.0438).  
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Figure 3.2. Potato extracts did not significantly reduce tumor weight (Fisher’s LSD at 
p<0.05). Tumor weight (g) is expressed as means ± SE.  
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3.2 MTA1 Expression in Tumors and Lungs  
Metastasis associated protein 1 (MTA1) supports cancer cell survival, angiogenesis, and 
metastasis (50). In prostate cancer cells, MTA1 silencing has been reported to promote 
apoptosis and reduce levels of vascular endothelial growth factor (VEGF) (50). Mice 
treated with the S. bulbocastanum extract had reduced MTA1 levels relative to the 
control and CO112F2-2P/P treatments (Figure 3.3A).  
 
Although rare, lung metastases have been reported in subcutaneous xenograft models of 
prostate cancer (56-58). Lung tissues were tested for MTA1 expression as an indicator of 
metastasis (Figure 3.3B). MTA1 was not detectable in the lungs of mice treated with the 
S. bulbocastanum extract and was only found in one of the mice treated with the 
CO112F2-2P/P extract, whereas three mice treated with the control had detectable 
MTA1 levels.   
 
3.3 VEGF Expression in Tumors 
Vascular endothelial growth factor is a putative regulator of angiogenesis and thus a 
common target for chemotherapy (44). High levels of VEGF are associated with cancer 
cell proliferation, survival, and metastasis (44,48). VEGF expression in mice treated 
with potato extracts was similar to that of mice treated with the control (Figure 3.4), 
suggesting that the potato extracts did not directly target angiogenesis.  
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A 
 
B 
 
Figure 3.3. MTA1 expression was lower in the tumors of mice treated with the S. 
bulbocastanum extract, while tumors from mice treated with the CO112F2-2P/P extract 
had comparable expression to the control (A). Both S. bulbocastanum and CO112F2-
2P/P extracts reduced MTA1 levels in lung tissues relative to the control, with greater 
reduction in mice treated with the S. bulbocastanum extract (B). Cell lysates were 
analyzed by Western blotting as described in the Materials and Methods and β-actin was 
used as a loading control. 
 
 
 
 
 
Figure 3.4. Neither potato extract reduced vascular endothelial growth factor (VEGF) 
levels in tumor tissue relative to the control treatment. Cell lysates were analyzed by 
Western blotting as described in the Materials and Methods.   
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3.4 Body Weight  
Body weight was monitored for the duration of the study to determine the impact of the 
potato extracts on overall health (Figure 3.5). There were no significant differences 
within or among treatment groups, but this measurement does not account for the 
contribution of tumor size to body weight.  
 
As a control, body weight was also measured in mice without tumors that received 
extracts from S. bulbocastanum (n = 4) and CO112F2-2P/P (n = 5) (Figure 3.6). There 
were no significant differences in body weight between the treatment groups. However, 
the final body weight of mice treated with the S. bulbocastanum extract was significantly 
greater than the initial body weight.   
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Figure 3.5.  Body weight of mice with tumors. Potato extracts did not cause any 
significant weight loss or gain over the duration of the study (Fisher’s LSD at p<0.05).  
 
 
 
 
 
Figure 3.6. In mice without tumors, there were no significant differences in body weight 
between the S. bulbocastanum and CO112F2-2P/P treatment groups. The CO112F2-
2P/P extract caused no significant weight gain or loss. The S. bulbocastanum extract 
induced a significant increase in body weight (*) relative to the initial body weight.  
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4. DISCUSSION AND SUMMARY 
 
Phytochemicals found in fruits and vegetables are associated with reduced risk of 
chronic diseases, including many cancers (2-10). As an affordable, nutrient dense food 
crop with high levels of consumption, dietary intake of potato is a potential means of 
chemoprevention (18). Breeding for increased content of phytochemicals in potato, such 
as phenolics, carotenoids, and glycoalkaloids, has the potential to increase amount of 
health promoting compounds in the diet, thus improving the market perception of both 
fresh and processed potato products (9,11-15).  
 
Our lab has previously demonstrated that specialty potato selections contain high levels 
of phenolics (18) and exhibit antiproliferative and pro-apoptotic activity in prostate 
cancer cell cultures (9,10). We aimed to further study the anti-prostate cancer activity of 
potato bioactives using a PC-3 xenograft mouse model. The goals of this study were to 
identify the effects of potato bioactives from different genotypes on tumor growth, 
factors related to cancer progression, and overall health. The purple-flesh breeding line 
CO112F2-2P/P was selected for this study based on high anthocyanin levels, phenolic 
content, and antioxidant activity (9,10,18), while a white-flesh wild relative of potato, S. 
bulbocastanum, was selected based on a unique glycoalkaloid profile (19). Multiple 
studies have demonstrated that phytochemicals reduce tumor size in PC-3 tumor 
xenograft models (59-61), but no significant reduction in tumor volume or weight 
(Figures 3.1 & 3.2) was observed in this study. The lack of a significant effect on tumor 
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volume could be due to an insufficient dosage of bioactives (26 mg CAE/kg/dose) and/or 
the physiology of the PC-3 cell line. A higher dosage of phenolics could have been 
administered by dosing prior to PC-3 cell injection, increasing the frequency of dosage, 
or dosage escalation. It is also worth noting that potato bioactives may exhibit greater 
antiproliferative activity on earlier stages of prostate cancer that exhibit androgen 
dependence or sensitivity. The PC-3 cell line was chosen for the ease of tumor 
establishment, but there are many transgenic mouse models that may be more 
appropriate. One such model is the ARR2PB-Myc model, in which prostate 
adenocarcinoma develops in accordance with the human disease, allowing evaluation of 
the early stages of prostate cancer (45). An additional benefit of using a transgenic 
model is that potato could be incorporated into the diet, which would more accurately 
model human consumption. 
 
In addition to tumor size, this study looked at proteins related to cancer aggressiveness. 
Kai et al. (50) reported that expression of metastasis associated protein 1 (MTA1) is 
correlated with cancer aggressiveness, angiogenesis, inhibition of apoptosis, and 
metastasis. Although there were no significant differences in tumor size, mice treated 
with the S. bulbocastanum extract showed lower levels of MTA1 in tumors than the 
CO112F2-2P/P and control treatments, which had comparable levels of MTA1 (Figure 
3.3A). Lung tissues were also analyzed for MTA1 expression as a measurement of 
metastasis, which has been reported in xenograft models (57,58). Both potato extracts 
reduced MTA1 levels in the lungs, with the S. bulbocastanum extract providing a greater 
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reduction than the CO112F2-2P/P extract (Figure 3.3B). The observed reduction of 
MTA1 suggests that bioactives in potato may have potential to reduce tumor growth, 
angiogenesis, and metastasis via downregulation of MTA1, but this conclusion requires 
verification in future studies. The reduction of MTA1 levels in lung tissue does not agree 
with the results of Li et al. (62), in which MTA1 was highly expressed in lungs of 
normal BALB/c mice. This difference could be due to differences in physiology between 
the mouse strains or differences between the MTA1 antibody used in each study.   
 
Angiogenesis is necessary for cancer progression, and is thus a common target for many 
chemotherapies (48). Vascular endothelial growth factor (VEGF) levels were measured 
in tumor tissues as an indication of angiogenic activity. It has also been reported that 
MTA1 and VEGF are positively correlated (50). Despite the reduced levels of MTA1, 
there were no detectable differences in VEGF expression among the treatment groups 
(Figure 3.4). It is possible that the duration of the study was not long enough to observe 
the impact of reduced MTA1 activity on VEGF levels. It is also important to note that 
this study only evaluated two proteins, which do not characterize the heterogeneity and 
complexity of the molecular pathways involved in prostate cancer. Determination of any 
significant effects of potato bioactives on prostate cancer would require the analysis of 
many factors related to cancer development, such as growth factors, kinases, cytokines, 
and various cell cycle regulators.  
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Toxicity of potato extracts was evaluated by monitoring body weight in mice with and 
without tumors. There was no significant weight loss or gain in mice with tumors 
(Figure 3.5). In mice without tumors, the CO112F2-2P/P extract had no significant 
impact on weight, while mice receiving the S. bulbocastanum extract experienced a 
significant weight gain (Figure 3.6). This was an unexpected result as glycoalkaloids are 
commonly associated with weight loss (34). However, many glycoalkaloids are not well 
characterized and may impact health differently. Histological analysis of vital organs is 
necessary to determine any toxicity induced by the potato extracts.  
 
In this study, potato bioactives did not significantly reduce tumor size or VEGF, but did 
reduce MTA1 levels. Reduction of MTA1 could have implications in the promotion and 
progression of prostate cancer. Bioactives from S. bulbocastanum were more effective at 
reducing MTA1 levels than bioactives from CO112F2-2P/P. The reduction of MTA1 
and observed increase in body weight may result from the unique glycoalkaloid profile 
of this species, which could provide a source of genetic diversity for beneficial 
compounds in a breeding program. However, more evidence is necessary to elucidate the 
role of potato bioactives in prostate cancer progression. This data could be obtained by 
repeating this study using a higher dosage of potato bioactives or by using a transgenic 
mouse model for prostate cancer in which potato could be incorporated into the diet.  
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